INT72558

Context Info Confidence 0.54 First Reported 1997 Last Reported 2008 Negated 2 Speculated 0 Reported most in Abstract Documents 6 Total Number 6 Disease Relevance 1.97 Pain Relevance 1.14

small molecule metabolic process (CYP2C19) oxidoreductase activity (CYP2C19) endoplasmic reticulum (CYP2C19) enzyme binding (CYP2C19)

Anatomy Link Frequency plasma 1 liver 1 CYP2C19 (Homo sapiens)

Pain Link Frequency Relevance Heat fluoxetine 2 99.04 Desipramine 2 94.88 Lamotrigine 3 81.12 Gabapentin 2 80.60 Antiepileptic agent 1 79.48 peptic ulcer disease 4 75.00 antiepileptic Drug 1 75.00 Angina 1 69.04 aspirin 1 67.32 cINOD 5 66.96

Disease Link Frequency Relevance Heat Toxicity 2 98.68 Hemorrhage 8 97.16 Ulcers 4 96.80 Hemorrhagic Shock 1 95.20 Disease 6 75.00 Cv General 3 Under Development 1 69.04 INFLAMMATION 3 66.40 Hepatotoxicity 4 65.92 Esophageal Varices 1 63.20 Hyperuricemia 31 61.44

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The levels of other CYP proteins, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, were not affected by eletriptan.

Neg (not) Regulation (affected) of CYP2C19

1) Confidence 0.54 Published 2000 Journal Drug Metab. Dispos. Section Abstract Doc Link 10611140 Disease Relevance 0.06 Pain Relevance 0.15

These data suggest that, in this patient, phenytoin toxicity was caused by inhibition of CYP2C19 by ticlopidine, and the data emphasize the importance of CYP2C19 in the metabolism of phenytoin.

Regulation (emphasize) of CYP2C19 associated with toxicity

2) Confidence 0.45 Published 1997 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 9390115 Disease Relevance 0.24 Pain Relevance 0.07

The metabolism of PPIs is dependent upon P450 2C19 genotypes and the clinical usefulness of genotypic analysis remains to be determined.

Regulation (dependent) of P450 2C19

3) Confidence 0.44 Published 2008 Journal J. Gastroenterol. Hepatol. Section Abstract Doc Link 19120905 Disease Relevance 1.42 Pain Relevance 0.43

Two aspects have been particularly taken into account: the changes or absence of changes in plasma/serum concentrations of concomitant drugs and the direct or indirect evidence of induction, inhibition or lack of effect on the six major human hepatic CYP isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4), as well as on other CYP isozymes or enzyme systems.

Regulation (effect) of CYP2C19 in plasma

4) Confidence 0.43 Published 2000 Journal Fundam Clin Pharmacol Section Abstract Doc Link 11030437 Disease Relevance 0 Pain Relevance 0.20

Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes.

Regulation (Effects) of CYP2C19 in liver associated with fluoxetine

5) Confidence 0.43 Published 2001 Journal Acta Pharmacol. Sin. Section Title Doc Link 11730569 Disease Relevance 0 Pain Relevance 0.19

Based on the in vitro study that showed febuxostat had a weak inhibitory effect on CYP2D6, but no effect on CYP1A2, CYP2C9, CYP2C19 or CYP3A4, Khosravan et al (2005b) examined the effect of multiple doses of febuxostat 120 mg daily on the pharmacokinetics of desipramine, a substrate for CYP2D6.

Neg (no) Regulation (effect) of CYP2C19 associated with desipramine

6) Confidence 0.19 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643102 Disease Relevance 0.25 Pain Relevance 0.09

General Comments

This test has worked.